EC Number | Application | Comment | Organism |
---|---|---|---|
2.7.8.27 | pharmacology | sphingomyelin synthase 2 (SMS2) is a potential therapeutic target for obesity and insulin resistance | Mus musculus |
EC Number | Cloned (Comment) | Organism |
---|---|---|
2.7.8.27 | gene Sgms2, relative real-time PCR expression analysis | Mus musculus |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
2.7.8.27 | additional information | generation of SMS2 KO mice | Mus musculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.8.27 | a ceramide + a phosphatidylcholine | Mus musculus | - |
a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? | |
2.7.8.27 | a ceramide + a phosphatidylcholine | Mus musculus C57BL/6N | - |
a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.8.27 | Mus musculus | Q9D4B1 | - |
- |
2.7.8.27 | Mus musculus C57BL/6N | Q9D4B1 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.7.8.27 | liver | - |
Mus musculus | - |
2.7.8.27 | skeletal muscle | - |
Mus musculus | - |
2.7.8.27 | white adipose tissue | - |
Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.8.27 | a ceramide + a phosphatidylcholine | - |
Mus musculus | a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? | |
2.7.8.27 | a ceramide + a phosphatidylcholine | - |
Mus musculus C57BL/6N | a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.7.8.27 | Sgms2 | - |
Mus musculus |
2.7.8.27 | SMS2 | - |
Mus musculus |
2.7.8.27 | sphingomyelin synthase 2 | - |
Mus musculus |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.7.8.27 | malfunction | glucose kinetics study using the radiolabeled glucose analog 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG), in wild-type (WT) and SMS2 knockout (KO) mice: insulin signaling is enhanced in the liver, white adipose tissue and skeletal muscle of SMS2 KO mice compared with those of wild-type mice. In addition, compared with in wild-type mice, blood clearance of 18F-FDG is accelerated in SMS2 KO mice when they are fed either a normal or a high fat diet. 18F-FDG uptake is also increased in insulin-targeted tissues such as skeletal muscle in the SMS2 KO mice, whereas skeletal muscle sphingolipid content is not clearly affected. Plasma levels of very long-chain fatty acid (VLCFA)-containing ceramides are markedly increased in SMS2 KO mice compared with in wild-type mice. Genetic inhibition of SMS2 elevates glucose clearance through activation of glucose uptake into insulin-targeted tissues such as skeletal muscle by a mechanism independent of hepatic SMS2. This occurs, at least in part, via indirect mechanisms such as elevation of VLCFA-containing ceramides | Mus musculus |
2.7.8.27 | physiological function | role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice | Mus musculus |